Invivogen
Menu

Anti-hEGFR-hIgG1fut

Anti-hEGFR-hIgG1fut Unit size Cat. code Docs Qty Price
Non-fucosylated monoclonal human IgG1 antibody against human EGFR
100 µg
hegfr-mab13
+-
$325.00

Non-fucosylated monoclonal human IgG1 antibody against human EGFR

Anti-hEGFR-hIgG1fut features the constant region of the human IgG1 isotype and the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets EGFR, a cell surface receptor overexpressed in many types of cancer. EGFR is activated by binding specific ligands, including epidermal growth factor and transforming growth factor-α. Activation of EGFR promotes cell proliferation and survival, as well as angiogenesis, leading to tumor growth and metastasis. Binding of cetuximab to EGFR blocks ligand-receptor binding and induces receptor internalization and subsequent degradation. Consequently, it blocks downstream pathways which regulate cell growth and angiogenesis. In addition, it induces cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) [1,2]. Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck  [3].

Anti-hEGFR-hIgG1 is a non-fucosylated antibody. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC) without any detectable change in complement-dependent cytotoxicity (CDC) or antigen binding capability [4,5]. This antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G.

Applications: Anti-hEGFR-hIgG1fut can be used with Anti-hEGFR-hIgG1 to compare the ADCC activity.

  1. Kurai J. et al., 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 3(5):1552-61.
  2. Kimura H. et al., 2007. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8):1275-80.
  3. Vincenzi B. et al., 2010. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 10(1):80-95.
  4. Yamane-Ohnuki N. & Satoh M., 2009. Production of therapeutic antibodies with controlled fucosylation. corresponding MAbs. 1:230–236.
  5. Mizushima T., 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 16: 1071–80.
Back to the top

Specifications

Specificity: Targets cells expressing human EGFR (Epidermal growth factor receptor)
Clonality: Monoclonal antibody
Isotype: Human IgG1
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.
Purity: Purified by affinity chromatography with protein G

Quality control:
- Binding to human EGFR has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

Back to the top

Contents

100 µg purified anti-hEGFR-hIgG1fut antibody, provided azide-free and lyophilized

Back to the top

Customer Service
& Technical Support

CAPTCHA
In order to prevent automated spam submissions, please answer the following question:
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Shopping cart is empty